Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG-MRI study of methylphenidate effects on neural mechanisms in adult ADHD and post-mood disorder attention deficit
2019-003049-13Phase 3Active
- Sponsor
- Strasbourg University Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Effect of methylphenidate on task-related brain activation. Started Jun 2022; status: active.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2019-003049-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003049-13.